Express Scripts 2009 Annual Report Download - page 48

Download and view the complete annual report

Please find page 48 of the 2009 Express Scripts annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 108

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108

Express Scripts 2009 Annual Report 46
EXE
CU
TI
V
E
SU
MMARY A
N
D TRE
N
D FA
C
T
O
R
S
AFFE
C
TI
NG
THE B
US
I
N
E
SS
O
ur results in 20
0
9
r
eflect the successful execution of our business model which emphasizes the alignment of ou
r
financial interests with those of our clients through greater use of generic
s
an
d
l
ow
-
cos
t
b
ran
ds
,
home delivery and specialt
y
pharmacy
.
I
n
2
00
9
,
we
be
n
e
fit
ed
fr
om
better management of ingredient costs through actions such as renegotiation of
s
upplier contracts, increased competition among generic manufactur
e
r
s
,
h
igher generic utilization (
6
8
.3
%
in 20
0
9
c
ompared to
6
6.
1
%
in 20
0
8
)
and other actions which helped to
r
educe ingredient cost
s
.
I
n addition, through the research
performed b
y
u
s and guided b
y
our
C
ente
r
f
or
C
ost
-
Effective Consumerism
,
we are providing our clients with additional
t
ools designed to generate higher generic fill rates and further increase the use of our home delivery and specialty pharmac
y
se
r
v
i
ces
an
d
d
ri
ve
g
reater adherenc
e
.
W
hile we believe we are well positioned fro
m
a business and financial perspective,
we are subject to the current adverse economic environment. Th
ese
co
n
d
iti
o
n
s
cou
l
d
aff
ec
t
ou
r
bus
in
ess
in a n
u
m
be
r
o
f
direct and indirect ways
.
A
dditionally, we have entered into
new
l
on
g
-
te
r
m
co
ntra
c
t
s
w
ith
W
ellPoi
n
t
and the DoD.
W
e
expect to have a highe
r
c
oncentration of revenues amon
g
t
h
ese
c
li
e
nt
s.
W
e b
e
l
ieve the positive trends we saw
i
n 2
00
9
,
including lower drug purchasing cost
s
and increased generic usag
e
,
s
hould continue to offset the negative impact
of
v
a
r
ious marketplace forces affecting pricing and plan structure, among
o
ther factors, and thus continue to generate improvements in our results of operations in the future.
C
RITI
C
AL A
CCOUN
TI
NG
P
O
LI
C
IE
S
The preparation of financial statements in conformity with accounting principles generally accepted in the United
States requires management to make estimates and assumptions
w
hi
c
haffect the reported amounts of assets and liabilities
at th
e
d
at
e
o
f th
e
fi
n
ancial statements and the reported amounts of revenues and expenses during the reporting period. Ou
r
estimates and assumptions are based upon a combination of historical information and various other assumptions believed
t
o be reasonable under the particu
l
ar circumstances. Actual results may differ from our estimates. Certain of the accounting
policie
s
w
hi
c
h
m
ost impact our consolidated financial statements and that require our management to make difficult,
s
ubjective or complex judgments are described bel
o
w. This should be read in conju
n
c
tion with Note 1, “Summary of
s
ignificant accounting p
o
li
c
i
es
” an
d
w
ith th
e
o
th
e
r n
o
t
es
t
o
th
e
co
n
so
li
d
at
ed
finan
c
ial
s
tat
e
m
e
nt
s.
R
EBATE A
CCOU
NTIN
G
ACCOU
NTIN
G
P
O
LI
C
Y
W
e administer a rebate program through which we recei
v
e rebates and administrative fees from pharmaceutical
m
anufacturers. The portion of rebates payable to clients is estimated based on historical and/or anticipated sharing
percentages. These estimates are adjusted to actual when amounts are paid to clie
n
ts.
FA
C
T
O
R
S
AFFE
C
TIN
G
E
S
TIMATE
Th
e
fa
c
t
o
r
s
t
h
a
t
c
ould impact our estimates of rebates, rebates receivable and rebates payable are as follows
:
Differences between estimated allocation percentages and actual rebate allocation percentages;
Drug patent expi
r
ations
;
and
C
hanges in drug utilization patterns
.
Historically, adjustments to our original estimates have bee
n
r
elativel
y
i
mmat
e
rial
.
ALL
OW
AN
C
E F
O
R D
OU
BTF
U
L A
CCOU
NT
S
ACCOU
NTIN
G
P
O
LI
C
Y
W
e provide an allowance for doubtful accounts equal to estimated
u
n
co
ll
ec
ti
b
l
e
r
ece
i
v
a
b
l
es.
Thi
s
es
timat
e
i
s
b
a
sed
o
n th
e
cu
rr
e
nt
s
tat
us
o
f
e
a
c
h
cus
t
o
m
e
r’
s
r
ece
i
v
a
b
l
e
b
alan
ce.
FA
C
T
O
R
S
AFFE
C
TIN
G
E
S
TIMATE
W
e record allowances for doubtful accounts based on a variety of factors including the length of time the
rece
i
v
a
b
l
e
s
are past due, the financial health of the customer and historical experience. Our estimate could be impacted b
y
c
hanges in economic and market conditions as well as changes to our customers’ financial condition
.